Immune checkpoints as therapeutic targets in autoimmunity

Frontiers in Immunology

Volumn 9, Issue OCT, 2018, Pages

  Paluch, Christopher ^a,b   Santos, Ana Mafalda ^a,c   Anzilotti, Consuelo ^a,c   Cornall, Richard J ^a,b   Davis, Simon J ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Agonist; Antibody; Autoimmunity; Immune checkpoint; Immunosuppression; Inhibitory receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL; AUTOIMMUNITY; DRUG EFFECT; HUMAN; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; CTLA-4 ANTIGEN; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85055170537     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.02306     Document Type: Review

References (92)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. (2010) 363:711-23. doi:10.1056/NEJMoa1003466.
2. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. (2015) 372:320-30. doi:10.1056/NEJMoa1412082.
3. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J Immunother Cancer (2018) 6:8. doi:10.1186/s40425-018-0316-z.
4. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol. (2015) 6:418. doi:10.3389/fimmu.2015.00418.
5. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer (2016) 54:139-48. doi:10.1016/j.ejca.2015.11.016.
6. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH.Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3:541-7. doi:10.1016/1074-7613(95)90125-6.
7. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 345:1623-7. doi:10.1126/science.1255904.
8. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 291:319-22. doi:10.1126/science.291.5502.319.
9. Nishimura H, Nose M, Hiai H, Minato N, and Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 11:141-51. doi:10.1016/S1074-7613(00)80089-8.
10. Prokunina L, Castillejo-López C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. (2002) 32:666-9. doi:10.1038/ng1020.
11. James ES, Harney S, Wordsworth BP, Cookson WO, Davis SJ, Moffatt MF. PDCD1: A tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun. (2005) 6:430-7. doi:10.1038/sj.gene.6364223.
12. Lee YH, Bae SC, Kim JH, Song GG. Meta-Analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol. (2015) 74:230-9. doi:10.1007/s00393-014-1415-y.
13. Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Mäurer M, et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol. (2005) 58:50-7. doi:10.1002/ana.20514.
14. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: Relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol. (2004) 155:172-82. doi:10.1016/j.jneuroim.2004.06.013.
15. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. (2003) 111:363-70. doi:10.1172/JCI16015.
16. Oya Y, Watanabe N, Owada T, Oki M, Hirose K, Suto A, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum. (2008) 58:2498-510. doi:10.1002/art.23674.
17. Oki M, Watanabe N, Owada T, Oya Y, Ikeda K, Saito Y, et al. A functional polymorphism in B and T lymphocyte attenuator is associated with susceptibility to rheumatoid arthritis. Clin Dev Immunol. (2011) 2011:305656. doi:10.1155/2011/305656.
18. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. (2011) 186:1338-42. doi:10.4049/jimmunol.1003081.
19. Yaghoobi E, Abedian S, Babani O, Izad M. TIM-3 Rs10515746 (A/C) and Rs10053538 (C/A) Gene polymorphisms and risk of multiple sclerosis. Iran J Public Health (2016) 45:644-49.
20. Chae SC, Park YR, Shim SC, Yoon KS, Chung HT. The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis. Immunol Lett. (2004) 95:91-5. doi:10.1016/j.imlet.2004.06.008.
21. Wang M, Ji B, Wang J, Cheng X, Zhou Q, Zhou J, et al. Tim-3 polymorphism downregulates gene expression and is involved in the susceptibility to ankylosing spondylitis. DNA Cell Biol. (2014) 33:723-8. doi:10.1089/dna.2014.2456.
22. Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. (2010). 62:1870-80. doi:10.1002/art.27500.
23. Wang G, Hu P, Yang J, Shen G, Wu X. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int. (2011) 31:513-9. doi:10.1007/s00296-009-1249-0.
24. Song MY, Hong CP, Park SJ, Kim JH, Yang BG, Park Y, et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut (2015) 64:260-71. doi:10.1136/gutjnl-2014-307311.
25. Gao W, Demirci G, Strom TB, Li XC. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-Term islet allograft survival. Transplantation (2003) 76:994-9. doi:10.1097/01.TP.0000085010.39567.FB.
26. Hirata S, Senju S, Matsuyoshi H, Fukuma D, Uemura Y, and Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol. (2005) 174:1888-97. doi:10.4049/jimmunol.174.4.1888.
27. Brown GR, Lee EL, El-Hayek J, Kintner K, Luck C. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-responses, and intestinal graft-versus-host disease. J Immunol. (2005) 174:4688-95. doi:10.4049/jimmunol.174.8.4688.
28. Ye Q, Fraser CC, Gao W, Wang L, Busfield SJ, Wang C, et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med. (2002) 195:795-800. doi:10.1084/jem.20012088.
29. Albring JC, Sandau MM, Rapaport AS, Edelson BT, Satpathy A, Mashayekhi M, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. (2010) 207:2551-59. doi:10.1084/jem.20102017.
30. Sakoda Y, Park JJ, Zhao Y, Kuramasu A, Geng D, Liu Y, et al. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood (2011) 117:2506-14. doi:10.1182/blood-2010-08-301325.
31. Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional Anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol. (2018) 200:3000-7 doi:10.4049/jimmunol.1700407.
32. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khourys SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. (2005) 6:1245-52. doi:10.1038/ni1271.
33. He W, Fang Z, Wang F, Wu K, Xu Y, Zhou H, et al. Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. Transplantation (2009) 88:782-90. doi:10.1097/TP.0b013e3181b47f25.
34. Wang F, He W, Zhou H, Yuan J, Wu K, Xu L, et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol. (2007) 250:68-74. doi:10.1016/j.cellimm.2008.01.006.
35. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. (2008) 127:78-88. doi:10.1016/j.clim.2008.01.006.
36. Gorczynski RM, Chen Z, Yu K, Hu J. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol. (2001) 101:328-34. doi:10.1006/clim.2001.5117.
37. Simelyte E, Criado G, Essex D, Uger RA, Feldmann M, Williams RO. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum. (2008) 58:1038-43. doi:10.1002/art.23378.
38. Gorczynski RM, Hu J, Chen Z, Kai Y, Lei J. A CD200FC immunoadhesin prolongs rat islet xenograft survival in mice. Transplantation (2002) 73:1948-53. doi:10.1097/00007890-200206270-00018.
39. Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, et al. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci. (2010) 30:2025-38. doi:10.1523/JNEUROSCI.4272-09.2010.
40. Gorczynski RM, Chen Z, Lee L, Yu K, Hu J. Anti-CD200R ameliorates collagen-induced arthritis in mice. Clin Immunol. (2002) 104:256-64. doi:10.1006/clim.2002.5232.
41. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. (2008) 9:1074-83. doi:10.1038/ni.1637.
42. Copland DA, Calder CJ, Raveney BJ, Nicholson LB, Phillips J, Cherwinski H, et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage\ activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol. (2007) 171:580-88. doi:10.2353/ajpath.2007.070272.
43. Prodeus A, Cydzik M, Abdul-Wahid A, Huang E, Khatri I, Gorczynski R, et al. Agonistic CD200R1 DNA aptamers are potent immunosuppressants that prolong allogeneic skin graft survival. Mol Ther Nucleic Acids (2014) 3:e190. doi:10.1038/mtna.2014.41.
44. Gorczynski RM, Chen Z, Shivagnahnam S, Taseva A, Wong K, Yu K, et al. Potent immunosuppression by a bivalent molecule binding to CD200R and TGF-betaR. Transplantation (2010) 90:150-9. doi:10.1097/TP.0b013e3181e2d6a1.
45. Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. (2011) 187:1537-41doi:10.4049/jimmunol.1100660.
46. Flies DB, Han X, Higuchi T, Zheng L, Sun J, Ye J, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. J Clin Invest. (2014) 124:1966-75. doi:10.1172/JCI74589.
47. Prodeus A, Abdul-Wahid A, Sparkes A, Fischer NW, Cydzik M, Chiang N, et al. VISTA.COMP -An engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses. JCI Insight (2017) 2:e94308. doi:10.1172/jci.insight.94308.
48. Cooper DN, Barondes SH. God must love galectins; he made so many of them. Glycobiology (1999) 9:979-84. doi:10.1093/glycob/9.10.979.
49. Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T\ lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA. (2005) 102:1116-21. doi:10.1073/pnas.0409071102.
50. Pierer M, Schulz A, Rossol M, Kendzia E, Kyburz D, Haentzschel H, et al. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. J Immunol. (2009) 182:3139-45. doi:10.4049/jimmunol.0713715.
51. Sturmhoefel K, Lee K, Gray GS, Thomas J, Zollner R, O'Toole M, et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res. (1999) 59:4964-72.
52. Tacke M, Hanke G, Hanke T, Hünig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28. Eur J Immunol. (1997) 27:239-47. doi:10.1002/eji.1830270136.
53. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. (2006). 355:1018-28. doi:10.1056/NEJMoa063842.
54. Krieg C, Han P, Stone R, Goularte OD, Kaye J. Functional analysis of B and T lymphocyte attenuator engagement on CD4+ and CD8+ T cells. J Immunol. (2005) 175:6420-7. doi: 10.4049/jimmunol.175.10.6420.
55. Hurchla MA, Sedy JR, Gavrieli M, Gavrielli M, Drake CG, Murphy TL, et al. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol. (2005) 174:3377-85. doi:10.4049/jimmunol.174.6.3377.
56. Cherwinski HM, Murphy CA, Joyce BL, Bigler ME, Song YS, Zurawski SM, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell \ function. J Immunol. (2005) 174:1348-56. doi:10.4049/jimmunol.174.3.1348.
57. Flies DB, Higuchi T, Chen L. Mechanistic assessment of PD-1H coinhibitory receptor-induced T cell tolerance to allogeneic antigens. J Immunol. (2015) 194:5294-304. doi:10.4049/jimmunol.1402648.
58. Walker LS, Sansom DM. Confusing signals: Recent progress in CTLA-4 biology. Trends Immunol. (2015) 36:63-70. doi:10.1016/j.it.2014.12.001.
59. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. (2006) 5:185-6. doi:10.1038/nrd1989.
60. Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. (2016) 137:327-30. doi:10.1016/j.jaci.2015.08.036.
61. Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, et al. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. (2000) 164:4433-42. doi:10.4049/jimmunol.164.9.4433.
62. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest. (2006) 116:2252-61. doi:10.1172/JCI27856.
63. Kasagi S, Kawano S, Okazaki T, Honjo T, Morinobu A, Hatachi S, et al. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol. (2010) 184:2337-47. doi:10.4049/jimmunol.0901652.
64. Wong M, La Cava A, Singh RP, Hahn BH. Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. J Immunol. (2010) 185:6563-71. doi:10.4049/jimmunol.0903401.
65. Wong M, La Cava A, Hahn BH. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J Immunol. (2013) 190:5402-10. doi:10.4049/jimmunol.1202382.
66. Šedý JR, Balmert MO, Ware BC, Smith W, Nemcovicova I, Norris PS, et al. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator. J Biol Chem. (2017) 292:21060-70. doi:10.1074/jbc.M117.813295.
67. He FR, Zhu HF, Huang H, Dai YD, Shen X, Wang M, et al. Programmed death-1 ligands-Transfected dendritic cells loaded with glutamic acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response. Clin Exp Immunol. (2008) 151:86-93. doi:10.1111/j.1365-2249.2007.03546.x.
68. Li F, Ravetch JV. A general requirement for FcRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle (2012) 11:3343-44. doi:10.4161/cc.21842.
69. Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective Fc?R engagement. Cancer Cell (2016) 29:820-31. doi:10.1016/j.ccell.2016.05.001.
70. White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell (2015) 27:138-48. doi:10.1016/j.ccell.2014.11.001.
71. Dushek O, Goyette J, van der Merwe PA. Non-catalytic tyrosine-phosphorylated receptors. Immunol Rev. (2012) 250:258-76. doi:10.1111/imr.12008.
72. Davis SJ, van der Merwe PA. The kinetic-segregation model: TCR triggering and beyond. Nat Immunol. (2006) 7:803-809. doi:10.1038/ni1369.
73. Belardi B, O'Donoghue GP, Smith AW, Groves JT, Bertozzi CR. Investigating cell surface galectin-mediated cross-linking on glycoengineered cells. J Am Chem Soc. (2012) 134:9549-52. doi:10.1021/ja301694s.
74. Grujic O, Stevens J, Chou RY, Weiszmann JV, Sekirov L, Thomson C, et al. Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and ßklotho agonist antibodies. Biochem Biophys Res Commun. (2017) 486:985-91. doi:10.1016/j.bbrc.2017.03.145.
75. Bartholomaeus P, Semmler LY, Bukur T, Boisguerin V, Römer PS, Tabares P, et al. Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-Triggered cytokine response. J Immunol. (2014) 192:2091-2098. doi:10.4049/jimmunol.1302461.
76. Williams EL, Tutt AL, French RR, Chan HT, Lau B, Penfold CA, et al. Development and characterisation of monoclonal antibodies specific for the murine inhibitory Fc?RIIB (CD32B). Eur J Immunol. (2012) 42:2109-2120. doi:10.1002/eji.201142302.
77. Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. (2018) 28:416-32. doi:10.1038/s41422-018-0011-0.
78. Zhang M, Howard K, Winters A, Steavenson S, Anderson S, Smelt S, et al. Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus. Clin Exp Immunol. (2011) 163:77-87. doi:10.1111/j.1365-2249.2010.04259.
79. Lühder F, Huang Y, Dennehy KM, Guntermann C, Müller I, Winkler E, et al. Topological requirements and signaling properties of T cell-Activating, anti-CD28 antibody superagonists. J Exp Med. (2003) 197:955-66. doi:10.1084/jem.20021024.
80. Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol. (2005) 6:271-9. doi:10.1038/ni1170.
81. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. (2008) 180:7028-38. doi:10.4049/jimmunol.180.10.7028.
82. Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell (2017) 31:383-95. doi:10.1016/j.ccell.2017.02.001.
83. Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-Associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. (1998) 161:4058-65.
84. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary (2016) 19:82-92. doi:10.1007/s11102-015-0671-4.
85. Pallardy M, Hünig T. Primate testing of TGN1412: Right target, wrong cell. Br J Pharmacol. (2010) 161:509-11. doi:10.1111/j.1476-5381.2010.00925.x.
86. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. (2013) 369:122-33. doi:10.1056/NEJMoa1302369.
87. Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. (2011) 208:395-407. doi:10.1084/jem.20100466.
88. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci USA. (2015) 112:6682-7. doi:10.1073/pnas.1420370112.
89. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. (2013) 19:4917-24. doi:10.1158/1078-0432.CCR-12-1972.
90. Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: Transplantation and autoimmunity. Nat Rev Nephrol. (2014) 10:14-24. doi:10.1038/nrneph.2013.183.
91. Murakami N, Riella LV. Co-inhibitory pathways and their importance in immune regulation. Transplantation (2014) 98:3-14. doi:10.1097/TP.0000000000000169.
92. Zhang Q, Vignali DA. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity (2016) 44:1034-51. doi:10.1016/j.immuni.2016.04.017.